Document is current
Any future updates will be listed below
-
Authors
Shah, Harendra Kumar
Prem, Sai https://orcid.org/0009-0004-5236-6132
Wu, Xiaobo
Liszewski, M Kathryn
Atkinson, John P
Singh, Abhay Kumar https://orcid.org/0000-0001-8399-7974
Kapoor, Vaishali https://orcid.org/0000-0002-7581-1487
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04314089 at ClinicalTrials.govnct03665129 at ClinicalTrials.govDocuments that mention this clinical trial
Safety and efficacy of complement factor H (CFH) inhibitor GT103 in advanced non-small cell lung cancer (NSCLC): Results of a phase Ib first in human dose escalation study.
https://doi.org/10.1200/jco.2024.42.16_suppl.e14588
Results from a first-in-human phase 1B study of a complement factor H inhibitor (GT103) in patients with non-small cell lung cancer (NSCLC).
https://doi.org/10.1200/jco.2023.41.16_suppl.9128
Complement system in cancer: friend or foe of immunotherapy
https://doi.org/10.1136/jitc-2025-013290
699 Interim results from a phase IB, first-in-human study of a novel complement factor h inhibitor (GT103) in patients with refractory non-small cell lung cancer (NSCLC)
https://doi.org/10.1136/jitc-2022-sitc2022.0699
nct04812535 at ClinicalTrials.govDocuments that mention this clinical trial
Complement system in cancer: friend or foe of immunotherapy
https://doi.org/10.1136/jitc-2025-013290
Neutrophils in the era of immune checkpoint blockade
https://doi.org/10.1136/jitc-2020-002242
nct04947033 at ClinicalTrials.govDocuments that mention this clinical trial
Complement system in cancer: friend or foe of immunotherapy
https://doi.org/10.1136/jitc-2025-013290
nct04919629 at ClinicalTrials.govDocuments that mention this clinical trial
Complement system in cancer: friend or foe of immunotherapy
https://doi.org/10.1136/jitc-2025-013290
Documents that mention this clinical trial
Complement system in cancer: friend or foe of immunotherapy
https://doi.org/10.1136/jitc-2025-013290
-
Funding
Funding for this research was provided by:
Department of Radiation Oncology, School of Medicine, Washington University in St. Louis (Startup funds)
National Institute of General Medical Sciences (R35 GM136352)
American Cancer Society (Institutional Research Grant IRG-24-1299098-64-IRG)
- License Information
